Jeff Yass’s Damora Therapeutics DMRA Stock Holding History

Jeff Yass’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,484	Closed	-$70K	–	12868
2022 Q3	$70K	Buy	+1,484	New	+$75.2K	﹤0.01%	11990

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Jeff Yass's DMRA Position: Q2 2026 in Review

Jeff Yass increased its Damora Therapeutics (DMRA) stake by 23% in Q2 2026, buying an estimated $54.2K and bringing the position to 12,009 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #10959.

Jeff Yass first reported a position in DMRA in Q4 2021 and has held it in 11 quarters since. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Jeff Yass held 12,009 shares of Damora Therapeutics worth $312K as of Q2 2026.
Jeff Yass bought 2,239 Damora Therapeutics shares in Q2 2026, an estimated $54.2K.
Damora Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10959 holding.
Jeff Yass first reported a position in Damora Therapeutics in Q4 2021 and has held it in 11 quarters since.
103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.